EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multi-ubiquitination of topoisomerase I in cells treated with camptothecin Studies in a yeast model system



Multi-ubiquitination of topoisomerase I in cells treated with camptothecin Studies in a yeast model system



Proceedings of the American Association for Cancer Research Annual Meeting 40: 106-107, March




(PDF 0-2 workdays service: $29.90)

Accession: 035349628

Download citation: RISBibTeXText



Related references

Ubiquitination of topoisomerase I in cells treated with camptothecin. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 429, 1996

Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Research 49(22): 6318-6323, 1989

SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. Proceedings of the National Academy of Sciences of the United States of America 92(14): 6299-6303, 1995

DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies. Experimental Cell Research 226(2): 292-301, 1996

Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells. Biochemistry 48(14): 3176-3185, 2009

The human mitochondrial DNA topoisomerase from camptothecin-resistant CEM/C2 is more sensitive to inhibition by camptothecin than is the nuclear topoisomerase. FASEB Journal 15(4): A520, March 7, 2001

Enhanced lethality to human breast cancer cells of neocarzinostatin by camptothecin and beta lapachone a novel dna topoisomerase i modulator with a different mode of action from camptothecin. Proceedings of the American Association for Cancer Research Annual Meeting 33: 433, 1992

Camptothecin induced dna cleavage sites and base sequence selectivity in topoisomerase i cdna relationship to gene mutations in camptothecin resistant cells. Proceedings of the American Association for Cancer Research Annual Meeting 33: 434, 1992

Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I. Nucleic Acids Research 34(4): 1121-1132, 2006

Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. Journal of Biological Chemistry 268(30): 22322-22330, 1993

Studies of topoisomerase protein levels in leukemic cells obtained from patients before and after treatment with 9-amino-camptothecin. Proceedings of the American Association for Cancer Research Annual Meeting 40: 210, March, 1999

The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Research 61(17): 6555-6562, 2001

Structure-activity relationships among camptothecin derivatives and topoisomerase I in yeast. Abstracts of the General Meeting of the American Society for Microbiology 99: 1, 1999

The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles. Biochemistry 38(27): 8605-8611, 1999

Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer ChemoTherapy and Pharmacology 42(5): 345-356, 1998